Cargando…

β-Boswellic Acid Suppresses Breast Precancerous Lesions via GLUT1 Targeting-Mediated Glycolysis Inhibition and AMPK Pathway Activation

Breast carcinoma is a multistep progressive disease. Precancerous prevention seems to be crucial. β-Boswellic acid (β-BA), the main component of the folk medicine Boswellia serrata (B. serrata), has been reported to be effective in various diseases including tumors. In this work, we demonstrated tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Bie, Fengjie, Zhang, Guijuan, Yan, Xianxin, Ma, Xinyi, Zhan, Sha, Qiu, Yebei, Cao, Jingyu, Ma, Yi, Ma, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194511/
https://www.ncbi.nlm.nih.gov/pubmed/35712503
http://dx.doi.org/10.3389/fonc.2022.896904
_version_ 1784726745006473216
author Bie, Fengjie
Zhang, Guijuan
Yan, Xianxin
Ma, Xinyi
Zhan, Sha
Qiu, Yebei
Cao, Jingyu
Ma, Yi
Ma, Min
author_facet Bie, Fengjie
Zhang, Guijuan
Yan, Xianxin
Ma, Xinyi
Zhan, Sha
Qiu, Yebei
Cao, Jingyu
Ma, Yi
Ma, Min
author_sort Bie, Fengjie
collection PubMed
description Breast carcinoma is a multistep progressive disease. Precancerous prevention seems to be crucial. β-Boswellic acid (β-BA), the main component of the folk medicine Boswellia serrata (B. serrata), has been reported to be effective in various diseases including tumors. In this work, we demonstrated that β-BA could inhibit breast precancerous lesions in rat disease models. Consistently, β-BA could suppress proliferation and induce apoptosis on MCF-10AT without significantly influencing MCF-10A. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis suggested that β-BA may interfere with the metabolic pathway. Metabolism-related assays showed that β-BA suppressed glycolysis and reduced ATP production, which then activated the AMPK pathway and inhibited the mTOR pathway to limit MCF-10AT proliferation. Further molecular docking analysis suggested that GLUT1 might be the target of β-BA. Forced expression of GLUT1 could rescue the glycolysis suppression and survival limitation induced by β-BA on MCF-10AT. Taken together, β-BA could relieve precancerous lesions in vivo and in vitro through GLUT1 targeting-induced glycolysis suppression and AMPK/mTOR pathway alterations. Here, we offered a molecular basis for β-BA to be developed as a promising drug candidate for the prevention of breast precancerous lesions.
format Online
Article
Text
id pubmed-9194511
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91945112022-06-15 β-Boswellic Acid Suppresses Breast Precancerous Lesions via GLUT1 Targeting-Mediated Glycolysis Inhibition and AMPK Pathway Activation Bie, Fengjie Zhang, Guijuan Yan, Xianxin Ma, Xinyi Zhan, Sha Qiu, Yebei Cao, Jingyu Ma, Yi Ma, Min Front Oncol Oncology Breast carcinoma is a multistep progressive disease. Precancerous prevention seems to be crucial. β-Boswellic acid (β-BA), the main component of the folk medicine Boswellia serrata (B. serrata), has been reported to be effective in various diseases including tumors. In this work, we demonstrated that β-BA could inhibit breast precancerous lesions in rat disease models. Consistently, β-BA could suppress proliferation and induce apoptosis on MCF-10AT without significantly influencing MCF-10A. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis suggested that β-BA may interfere with the metabolic pathway. Metabolism-related assays showed that β-BA suppressed glycolysis and reduced ATP production, which then activated the AMPK pathway and inhibited the mTOR pathway to limit MCF-10AT proliferation. Further molecular docking analysis suggested that GLUT1 might be the target of β-BA. Forced expression of GLUT1 could rescue the glycolysis suppression and survival limitation induced by β-BA on MCF-10AT. Taken together, β-BA could relieve precancerous lesions in vivo and in vitro through GLUT1 targeting-induced glycolysis suppression and AMPK/mTOR pathway alterations. Here, we offered a molecular basis for β-BA to be developed as a promising drug candidate for the prevention of breast precancerous lesions. Frontiers Media S.A. 2022-05-31 /pmc/articles/PMC9194511/ /pubmed/35712503 http://dx.doi.org/10.3389/fonc.2022.896904 Text en Copyright © 2022 Bie, Zhang, Yan, Ma, Zhan, Qiu, Cao, Ma and Ma https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Bie, Fengjie
Zhang, Guijuan
Yan, Xianxin
Ma, Xinyi
Zhan, Sha
Qiu, Yebei
Cao, Jingyu
Ma, Yi
Ma, Min
β-Boswellic Acid Suppresses Breast Precancerous Lesions via GLUT1 Targeting-Mediated Glycolysis Inhibition and AMPK Pathway Activation
title β-Boswellic Acid Suppresses Breast Precancerous Lesions via GLUT1 Targeting-Mediated Glycolysis Inhibition and AMPK Pathway Activation
title_full β-Boswellic Acid Suppresses Breast Precancerous Lesions via GLUT1 Targeting-Mediated Glycolysis Inhibition and AMPK Pathway Activation
title_fullStr β-Boswellic Acid Suppresses Breast Precancerous Lesions via GLUT1 Targeting-Mediated Glycolysis Inhibition and AMPK Pathway Activation
title_full_unstemmed β-Boswellic Acid Suppresses Breast Precancerous Lesions via GLUT1 Targeting-Mediated Glycolysis Inhibition and AMPK Pathway Activation
title_short β-Boswellic Acid Suppresses Breast Precancerous Lesions via GLUT1 Targeting-Mediated Glycolysis Inhibition and AMPK Pathway Activation
title_sort β-boswellic acid suppresses breast precancerous lesions via glut1 targeting-mediated glycolysis inhibition and ampk pathway activation
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194511/
https://www.ncbi.nlm.nih.gov/pubmed/35712503
http://dx.doi.org/10.3389/fonc.2022.896904
work_keys_str_mv AT biefengjie bboswellicacidsuppressesbreastprecancerouslesionsviaglut1targetingmediatedglycolysisinhibitionandampkpathwayactivation
AT zhangguijuan bboswellicacidsuppressesbreastprecancerouslesionsviaglut1targetingmediatedglycolysisinhibitionandampkpathwayactivation
AT yanxianxin bboswellicacidsuppressesbreastprecancerouslesionsviaglut1targetingmediatedglycolysisinhibitionandampkpathwayactivation
AT maxinyi bboswellicacidsuppressesbreastprecancerouslesionsviaglut1targetingmediatedglycolysisinhibitionandampkpathwayactivation
AT zhansha bboswellicacidsuppressesbreastprecancerouslesionsviaglut1targetingmediatedglycolysisinhibitionandampkpathwayactivation
AT qiuyebei bboswellicacidsuppressesbreastprecancerouslesionsviaglut1targetingmediatedglycolysisinhibitionandampkpathwayactivation
AT caojingyu bboswellicacidsuppressesbreastprecancerouslesionsviaglut1targetingmediatedglycolysisinhibitionandampkpathwayactivation
AT mayi bboswellicacidsuppressesbreastprecancerouslesionsviaglut1targetingmediatedglycolysisinhibitionandampkpathwayactivation
AT mamin bboswellicacidsuppressesbreastprecancerouslesionsviaglut1targetingmediatedglycolysisinhibitionandampkpathwayactivation